McGlone Suttner Wealth Management Inc. Increases Position in Gilead Sciences, Inc. (NASDAQ:GILD)

McGlone Suttner Wealth Management Inc. boosted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 5.1% during the fourth quarter, Holdings Channel.com reports. The firm owned 4,142 shares of the biopharmaceutical company’s stock after acquiring an additional 201 shares during the quarter. McGlone Suttner Wealth Management Inc.’s holdings in Gilead Sciences were worth $336,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of GILD. PCA Investment Advisory Services Inc. purchased a new stake in Gilead Sciences in the second quarter worth about $25,000. OFI Invest Asset Management bought a new position in shares of Gilead Sciences in the third quarter worth approximately $26,000. Tompkins Financial Corp lifted its stake in shares of Gilead Sciences by 223.1% in the third quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 241 shares in the last quarter. Union Savings Bank bought a new position in shares of Gilead Sciences in the second quarter worth approximately $29,000. Finally, Fortitude Family Office LLC bought a new position in shares of Gilead Sciences in the fourth quarter worth approximately $29,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Buying and Selling at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 5,000 shares of the business’s stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $85.78, for a total value of $428,900.00. Following the sale, the chief financial officer now directly owns 101,534 shares in the company, valued at approximately $8,709,586.52. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, CFO Andrew D. Dickinson sold 5,000 shares of the business’s stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $85.78, for a total value of $428,900.00. Following the sale, the chief financial officer now directly owns 101,534 shares in the company, valued at approximately $8,709,586.52. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $73.18, for a total transaction of $146,360.00. Following the completion of the sale, the insider now owns 100,936 shares in the company, valued at $7,386,496.48. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 15,242 shares of company stock worth $1,277,726. Insiders own 0.16% of the company’s stock.

Gilead Sciences Price Performance

Shares of NASDAQ GILD traded up $0.24 during midday trading on Thursday, reaching $73.25. The stock had a trading volume of 8,369,466 shares, compared to its average volume of 7,613,002. The stock has a 50-day moving average of $75.11 and a 200-day moving average of $77.29. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.27 and a current ratio of 1.43. The company has a market capitalization of $91.20 billion, a price-to-earnings ratio of 16.40, a price-to-earnings-growth ratio of 0.92 and a beta of 0.18. Gilead Sciences, Inc. has a 12-month low of $71.37 and a 12-month high of $87.86.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.76 by ($0.04). The firm had revenue of $7.12 billion during the quarter, compared to analysts’ expectations of $7.10 billion. Gilead Sciences had a return on equity of 38.85% and a net margin of 20.89%. The business’s revenue for the quarter was down 3.7% on a year-over-year basis. During the same period last year, the company earned $1.67 earnings per share. As a group, research analysts anticipate that Gilead Sciences, Inc. will post 7.07 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 28th. Shareholders of record on Friday, March 15th will be issued a $0.77 dividend. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.75. This represents a $3.08 dividend on an annualized basis and a yield of 4.20%. The ex-dividend date of this dividend is Thursday, March 14th. Gilead Sciences’s payout ratio is currently 68.44%.

Analysts Set New Price Targets

GILD has been the topic of a number of research analyst reports. Royal Bank of Canada lowered their price objective on shares of Gilead Sciences from $76.00 to $75.00 and set a “sector perform” rating on the stock in a research report on Wednesday, February 14th. Barclays lowered their price objective on shares of Gilead Sciences from $85.00 to $80.00 and set an “equal weight” rating on the stock in a research report on Monday, February 12th. Oppenheimer lowered their price objective on shares of Gilead Sciences from $115.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, February 12th. Cantor Fitzgerald lowered their price objective on shares of Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 7th. Finally, Mizuho lowered their price objective on shares of Gilead Sciences from $101.00 to $90.00 and set a “buy” rating on the stock in a research report on Thursday, February 22nd. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Gilead Sciences has a consensus rating of “Hold” and a consensus target price of $85.36.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.